Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study

Diabetes Care

Volumn 34, Issue 4, 2011, Pages 916-922

  Lewis, James D ^a   Ferrara, Assiamira ^b   Peng, Tiffany ^b   Hedderson, Monique ^b   Bilker, Warren B ^a   Quesenberry Jr , Charles P ^b   Vaughn, David J ^a   Nessel, Lisa ^a   Selby, Joseph ^b   Strom, Brian L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; HEMOGLOBIN A1C; INSULIN; METFORMIN; MIGLITOL; PIOGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; BLADDER CANCER; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY CANCER; FEMALE; GENDER; HEART FAILURE; HUMAN; INCOME; KIDNEY FUNCTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; RACE; REGISTER; SMOKING; UNITED STATES;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 79956217900     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1068     Document Type: Article

References (25)

1. Yoshimura R, Matsuyama M, Segawa Y, et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 2003;104:597-602 (Pubitemid 36337259)
2. Nakashiro KI, Hayashi Y, Kita A, et al. Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol 2001;159:591-597 (Pubitemid 32751089)
3. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999;1:330-339
4. Tontonoz P, Singer S, Forman BM, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 1997;94:237-241 (Pubitemid 27027193)
5. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58:3344-3352 (Pubitemid 28371075)
6. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86:2170-2177 (Pubitemid 32472935)
7. Elstner E, Müller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998;95:8806-8811
8. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
9. Takeda Pharmaceuticals America, Inc. Actos (Pioglitazone Hydrochloride) Tablets: Full Prescribing Information. 2009; Available from http://www.actos. com/actospro/home.aspx. Accessed 26 August 2010
10. Cohen SM. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci 2005;87:322-327 (Pubitemid 41300679)
11. Oliveria SA, Koro CE, Yood MU, Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2008;2:47-57 (Pubitemid 351194192)
12. Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007;25:1476-1481 (Pubitemid 46733074)
13. Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 2007;16:485-492 (Pubitemid 46824269)
14. Monami M, Lamanna C, Marchionni N, Mannucci E. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 2008;31:1455-1460
15. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289 (Pubitemid 41416583)
16. Friedman G, Habel L, Boles M, Mcfarland B. Kaiser Permanente Medical Care Program: Division of Research, Northern California, and Center for Health Research, Northwest Division. In Pharmacoepidemiology. 3rd ed. Strom BL, Ed. West Sussex, U.K., John Wiley & Sons, 2000, p. 263-283
17. Samaratunga H, Makarov DV, Epstein JI. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology 2002;60:315-319 (Pubitemid 34831779)
18. Cheng L, Neumann RM, Bostwick DG. Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications. Cancer 1999;86:2102-2108 [see comment]
19. Surveillance Epidemiology and End Results Fast Stats. 2010. National Cancer Institute, Rockville, MD; Available from http://seer.cancer.gov/ faststats/. Accessed 26 August 2010
20. Dominick MA, White MR, Sanderson TP, et al. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol 2006;34:903-920 (Pubitemid 46011143)
21. Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl) nitrosamine-induced urinary bladder cancers. Int J Cancer 2008;123:2254-2259
22. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006;49:2819-2823 (Pubitemid 44730282)
23. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-1305 (Pubitemid 40813563)
24. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010;60:207-221
25. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777